Loading
For cancers too rare or too poor to attract companies, run drug discovery in the open, the way neglected tropical diseases are tackled, and take candidates to first human trials with public money.
Paediatric cancers, rare adult cancers and cancers concentrated in low-income countries (Burkitt lymphoma, Kaposi sarcoma, oesophageal squamous cancer in East Africa) receive little industry investment. The Drugs for Neglected Diseases initiative delivered new treatments through open, partnered development. The proposal is an oncology equivalent: open target selection, shared compound libraries, contract chemistry and preclinical development, patent-free or non-exclusive licensing, and public or philanthropic funding through phase 2, with generic manufacturers engaged early.
Shares Funding follows fashion, not burden, Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Secrecy and intellectual property block collaboration, Rare and paediatric cancers without markets.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Funding follows fashion, not burden, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
Shares Funding follows fashion, not burden, Oesophageal cancer, Sarcomas (soft tissue, bone, GIST).
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).